Core Insights - The biotech sector had a strong performance last year but is starting slowly this year, with a favorable macro backdrop noted by industry experts [2] - There is optimism in the sector due to projected annual revenue of $200 billion for pharma by 2030 and significant capital available for investment [3] - AI is viewed as a supportive tool for biotech rather than a replacement, emphasizing the need for biological processes in drug development [3] Biotech Sector Overview - Eli Casdin, CEO of Casdin Capital, highlighted a disconnect in the biotech sector's performance, noting $225 billion in M&A activity that supports valuations [2] - The healthcare sector is currently outperforming, with staples and utilities also showing strong performance since the beginning of the year [4] - Steven Wieting, CIO Group chief investment strategist, expressed a strong overweight position in healthcare due to its previous underperformance and low correlation to tech [5] Company Highlights - Innoviva, Inc. (NASDAQ:INVA) reported fiscal Q4 revenue of $114.6 million, exceeding expectations, with a durable royalties portfolio generating $58.4 million in Q4 and $250.3 million for the full year [10][11] - Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) announced fiscal Q4 net revenues of $57.6 million, reflecting a 217% increase from FY24, and aims for profitability by early Q3 of 2026 [13][14]